Aspen Neuroscience
Aspen Neuroscience develops and delivers autologous cell replacement therapies for patients with high unmet medical need, beginning with Parkinson’s disease.
$115M Series B+ ·
Led by Frazier Life Sciences · Source: fundraisingfox.com
Total raised: $339M across 4 sourced rounds
All 4 rounds ↓Signals
About Aspen Neuroscience
It uses a person’s own cells to help restore function. Aspen Neuroscience aims to make personalized cell therapy commercially viable at scale.
Aspen Neuroscience | 435 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $115M | fundraisingfox.com | ||
| Series B+ | $147.5M | sdbj.com | ||
| Series A | $70M | blog.socaltech.com | ||
| Seed | $6.5M | finsmes.com |
Timeline
- X account created
- Website created
Founders and team
AB
Andrés Bratt-Leal Co-FounderLinkedIn · source: aspenneuroscience.comJL
Jeanne Loring FounderAS
Ana Sousa Chief Regulatory OfficerDM
Damien McDevitt President and Chief Executive OfficerKF
Kameel Farag CFOKR
Kim Raineri Chief Technology OfficerLJ
Lisa Johnson-Pratt Senior Vice President, Therapeutic Program LeadXZ
Xiaokui Zhang Chief Scientific Officer
Investors
AAlexandria Venture Investments
AARCH Venture Partners
AAxon Ventureslead investor
BBalyasny Asset Management
CCormorant Asset Management
DDomain Associateslead investorFFrazier Healthcare Partners
FFrazier Life Scienceslead investor
GGVlead investor
KKite Pharma
LLifeforce Capital
LLYFE Capitallead investor
MMedical Excellence CapitalMMirae Asset Capital
- NNewton Investment Management
NNS Investment
OOrbiMedlead investor
- PPrebys Ventures
RRevelation Partnerslead investor
SS32
SSam Altman
Companies like Aspen Neuroscience
CClaris Bio$118M Series B+ · Jul 2026
TTolerance Bio$17.2M Seed · Oct 2024MMirador Therapeutics$250M Series B+ · Jan 2026
OOri Biotech$100M Series B+ · Jan 2022
HHotSpot Therapeutics$100M Series B+ · Nov 2021
SSynuCa TherapeuticsSeed · Mar 2026
Other companies backed by Frazier Life Sciences
RRQ Bio$115M Series A · Jun 2026
IImmutrin$86.45M Series A · Mar 2026
AAngitia Bio$130M Series B+ · Feb 2026
AAirNexis Therapeutics$200M Series A · Jan 2026
TTubulis$360M Series B+ · Oct 2025AAlpha-9 Oncology$175M Series B+ · Oct 2024
Frazier Life Sciences portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/aspen-neuroscience (get a free API key).